As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > REGULATORY
REGULATORY
- MHLW to Promote Master Protocol Trials to Boost Efficiency in New Drug Development
March 14, 2019
- MHLW Likely to Tweak PMD Law Amendment Bill as Lawmaker Frowns on Order to Change Pharmaceutical Affairs Officer
March 13, 2019
- MHLW Panel Approves Shift from “Relative Contraindications” to “Contraindications” for 5 Drugs/Drug Groups
March 13, 2019
- Detailing Guidelines Casting Clouds over Drug Maker-Sponsored Press Seminars?
March 12, 2019
- Japan Issues 1st Guidance on Cancer Immunotherapy Development
March 11, 2019
- Govt to Ponder Appropriate Ways to Offer Off-Label Info to Patients
March 11, 2019
- LDP Wraps Up Review on Bill to Amend PMD Law; Cabinet OK Eyed in Mid-March
March 8, 2019
- LDP Panels Approve Proposal to Promote Regulatory Harmonization, Improve Access in Asia
March 8, 2019
- Chuikyo Approves Discussion Timeline for FY2020 Reimbursement Reform; Drug Pricing Debates Expected from June
March 7, 2019
- MHLW Grants Orphan Status to Adcetris, Evocalcet and More
March 6, 2019
- PMDA Sacks Employee for Doing Side Business with Companies with COI
March 5, 2019
- Xofluza Ordered to Add Hemorrhage Risk to Its Label
March 4, 2019
- Tagrisso Label Notes Previous Opdivo Use as Risk Factor for ILD
March 1, 2019
- MHLW to Impose Administrative Fines Only on Misleading Ads, Eyes 4.5% Charge: PMD Law
February 28, 2019
- MHLW Bureau Chief Eager to Hold Public-Private Confab towards 2020 Pricing Reform
February 28, 2019
- Kymriah Will Only Have Limited Impact on Health Finances: Minister
February 27, 2019
- Industry Official Prods Govt to Grant PMP to Repositioned Drugs Too
February 26, 2019
- Drug Prices Should Be Lowered in Areas with Needs Met, Like Lifestyle Disease: Prof.
February 26, 2019
- MHLW Panel Clears Biktarvy, Trelegy, Dupixent Asthma Use; Actemra OK’ed for CAR-T Side Effect
February 25, 2019
- Takecab, Clozaril under PMDA Risk Review
February 25, 2019
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…